Monoclonal Antibodies For Cancer Market Product Type (Bevacizumab, Cetumaximab, Ipilimumab, Nivolumab, Pembrolizumab, Pertuzumab, Rituximab, Trastuzumab Trastuzumab and Emtansine), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Blood Cancer, Melanoma, Liver Cancer and Others), Source (Humanized mAb, Human mAb and Chimeric mAb), End-User (Hospitals, Research Institutes and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: Feb 2025
- Report ID: 140958
- Number of Pages: 296
- Format:
-
keyboard_arrow_up
-
-
- Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Merck & Co.
- GSK plc.
- Johnson & Johnson
- Novartis AG Company Profile
- AstraZeneca Plc Company Profile
- Eli Lilly and Company
- AbbVie Inc. Company Profile
- Amgen, Inc.
- settingsSettings
Our Clients
- 140958
- Feb 2025
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
